Attralus Presents New Data on Its Pan-Amyloid Therapeutic and Diagnostic Candidates at the XIX International Symposium on Amyloidosis (ISA) AT-02, the company’s lead pan-amyloid removal therapeutic candidate, is currently being evaluated in a Phase 1 three-part trial and a Phase 2 open label extension trial in ATTR and AL amyloidosis...